Loading clinical trials...
Loading clinical trials...
CONNected Electronic Inhalers Asthma Control Trial 2 ("CONNECT 2"), a 24-Week Treatment, Multicenter, Open-Label, Randomized, Parallel Group Comparison, Feasibility Study of Standard of Care Treatment Versus the eMDPI Digital System, to Optimize Outcomes in Patients at Least 13 Years of Age or Older With Asthma
Conditions
Interventions
Fluticasone propionate/salmeterol (FS)
Albuterol
+2 more
Locations
46
United States
Teva Investigational Site 14971
Phoenix, Arizona, United States
Teva Investigational Site 14974
Fountain Valley, California, United States
Teva Investigational Site 14982
Los Angeles, California, United States
Teva Investigational Site 14945
San Diego, California, United States
Teva Investigational Site 14946
San Diego, California, United States
Teva Investigational Site 14966
Colorado Springs, Colorado, United States
Start Date
February 16, 2021
Primary Completion Date
March 4, 2022
Completion Date
March 10, 2022
Last Updated
March 14, 2023
NCT06979323
NCT06664619
NCT07431021
NCT07383896
NCT07356310
NCT07282886
Lead Sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions